Literature DB >> 22883617

Iron homeostasis during cystic fibrosis pulmonary exacerbation.

Alex H Gifford1, Lisa A Moulton, Dana B Dorman, Gordana Olbina, Mark Westerman, H Worth Parker, Bruce A Stanton, George A O'Toole.   

Abstract

BACKGROUND: Hypoferremia is a marker of disease severity in cystic fibrosis (CF). The effect of systemic antibiotics on iron homeostasis during CF pulmonary exacerbation (CFPE) is unknown. Our central hypotheses were that, by the completion of treatment, serum iron would increase, serum concentrations of interleukin-6 (IL-6) and hepcidin-25, two mediators of hypoferremia, would decrease, and sputum iron would decrease.
METHODS: Blood and sputum samples were collected from 12 subjects with moderate-to-severe CF (median percentage-predicted forced expiratory volume in 1 second (FEV(1) %) = 29%; median weight = 56 kg) within 24 hours of starting and completing a course of systemic antibiotics.
RESULTS: After treatment, subjects showed median FEV(1) % and body weight improvements of 4.5% and 2.0 kg, respectively (p < 0.05). Median serum iron rose by 2.4 μmol/L (p < 0.05), but 75% of patients remained hypoferremic. Median serum IL-6 and hepcidin-25 levels fell by 12.1 pg/mL and 37.5 ng/mL, respectively (p < 0.05). Median serum erythropoietin (EPO) and hemoglobin levels were unaffected by treatment. We observed a trend toward lower sputum iron content after treatment.
CONCLUSIONS: Hypoferremia is a salient characteristic of CFPE that improves with waning inflammation. Despite antibiotic treatment, many patients remain hypoferremic and anemic because of ineffective erythropoiesis.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22883617      PMCID: PMC3419499          DOI: 10.1111/j.1752-8062.2012.00417.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  31 in total

1.  THE DIAGNOSIS OF IRON DEFICIENCY ANEMIA.

Authors:  D F BAINTON; C A FINCH
Journal:  Am J Med       Date:  1964-07       Impact factor: 4.965

2.  What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis.

Authors:  J Abbott; A Holt; A Hart; A M Morton; L MacDougall; M Pogson; G Milne; H C Rodgers; S P Conway
Journal:  J Cyst Fibros       Date:  2009-08-08       Impact factor: 5.482

3.  Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels.

Authors:  Paaladinesh Thavendiranathan; Akshay Bagai; Albert Ebidia; Allan S Detsky; Niteesh K Choudhry
Journal:  J Gen Intern Med       Date:  2005-06       Impact factor: 5.128

4.  The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability.

Authors:  Sophie Moreau-Marquis; Jennifer M Bomberger; Gregory G Anderson; Agnieszka Swiatecka-Urban; Siying Ye; George A O'Toole; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-03-21       Impact factor: 5.464

5.  Autocrine formation of hepcidin induces iron retention in human monocytes.

Authors:  Igor Theurl; Milan Theurl; Markus Seifert; Sabine Mair; Manfred Nairz; Holger Rumpold; Heinz Zoller; Rosa Bellmann-Weiler; Harald Niederegger; Heribert Talasz; Günter Weiss
Journal:  Blood       Date:  2007-12-11       Impact factor: 22.113

Review 6.  Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway.

Authors:  Sophie Moreau-Marquis; Bruce A Stanton; George A O'Toole
Journal:  Pulm Pharmacol Ther       Date:  2008-01-29       Impact factor: 3.410

7.  Immunoassay for human serum hepcidin.

Authors:  Tomas Ganz; Gordana Olbina; Domenico Girelli; Elizabeta Nemeth; Mark Westerman
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

8.  Effectiveness of home treatment for patients with cystic fibrosis: the intravenous administration of antibiotics to treat respiratory infections.

Authors:  A Termoz; S Touzet; S Bourdy; E Decullier; L Bouveret; C Colin; R Nove-Josserand; P Reix; C Cracowski; I Pin; G Bellon; I Durieu
Journal:  Pediatr Pulmonol       Date:  2008-09

Review 9.  Iron acquisition by Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis.

Authors:  Iain L Lamont; Anna F Konings; David W Reid
Journal:  Biometals       Date:  2009-01-07       Impact factor: 2.949

Review 10.  Iron absorption and metabolism.

Authors:  Gregory J Anderson; David M Frazer; Gordon D McLaren
Journal:  Curr Opin Gastroenterol       Date:  2009-03       Impact factor: 3.287

View more
  17 in total

1.  Microbial Metabolite Signaling Is Required for Systemic Iron Homeostasis.

Authors:  Nupur K Das; Andrew J Schwartz; Gabrielle Barthel; Naohiro Inohara; Qing Liu; Amanda Sankar; David R Hill; Xiaoya Ma; Olivia Lamberg; Matthew K Schnizlein; Juan L Arqués; Jason R Spence; Gabriel Nunez; Andrew D Patterson; Duxin Sun; Vincent B Young; Yatrik M Shah
Journal:  Cell Metab       Date:  2019-11-07       Impact factor: 27.287

2.  Perspectives on anemia and iron deficiency from the cystic fibrosis care community.

Authors:  Gretchen M Garlow; Lucy S Gettle; Nicola J Felicetti; Deepika Polineni; Alex H Gifford
Journal:  Pediatr Pulmonol       Date:  2019-03-28

3.  Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis.

Authors:  Alex H Gifford; Diana M Alexandru; Zhigang Li; Dana B Dorman; Lisa A Moulton; Katherine E Price; Thomas H Hampton; Mitchell L Sogin; Jonathan B Zuckerman; H Worth Parker; Bruce A Stanton; George A O'Toole
Journal:  J Cyst Fibros       Date:  2013-12-13       Impact factor: 5.482

4.  Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity.

Authors:  Matthew R Hendricks; Lauren P Lashua; Douglas K Fischer; Becca A Flitter; Katherine M Eichinger; Joan E Durbin; Saumendra N Sarkar; Carolyn B Coyne; Kerry M Empey; Jennifer M Bomberger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

5.  What is hepcidin telling us about the natural history of cystic fibrosis?

Authors:  A H Gifford
Journal:  J Cyst Fibros       Date:  2014-04-30       Impact factor: 5.482

Review 6.  Effects of Pseudomonas aeruginosa on CFTR chloride secretion and the host immune response.

Authors:  Bruce A Stanton
Journal:  Am J Physiol Cell Physiol       Date:  2017-01-25       Impact factor: 4.249

7.  Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations.

Authors:  A H Gifford; A B Nymon; A Ashare
Journal:  Pediatr Pulmonol       Date:  2013-06-18

Review 8.  Iron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies.

Authors:  Jean Tyrrell; Máire Callaghan
Journal:  Microbiology (Reading)       Date:  2015-12-04       Impact factor: 2.777

9.  Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis.

Authors:  Alex H Gifford; Dana B Dorman; Lisa A Moulton; Jennifer E Helm; Mary M Griffin; Todd A MacKenzie
Journal:  Clin Transl Sci       Date:  2015-12-08       Impact factor: 4.689

10.  CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis.

Authors:  Alex H Gifford; Sonya L Heltshe; Christopher H Goss
Journal:  Ann Am Thorac Soc       Date:  2019-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.